Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Linda Evans
Observed names:
Evans, Linda,
L Evans,
L S Evans,
L. Evans,
Linda S Evans,
Linda Susan Evans
show all 6
Observed institutions:
Yorkshire Cancer Research,
Weston Park Cancer Centre,
Sheffield Teaching Hospitals NHS Foundation Trust
OpenAlex ID:
A5111761640
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
2021
·
Thomas Powles
, Tibor Csőszi
, et al.
·
The Lancet Oncology
·
642
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
2020
·
Thomas Powles
, Michiel S van der Heijden
, et al.
·
The Lancet Oncology
·
501
PDF
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
2009
·
J W Valle
, H Wasan
, et al.
·
British Journal of Cancer
·
271
PDF
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
2018
·
M.R. Sydes
, M.R. Spears
, et al.
·
Annals of Oncology
·
250
PDF
Non-Hodgkin lymphoma
2003
·
Linda S Evans
, Barry W Hancock
·
The Lancet
·
134
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
2012
·
A.F.C. Okines
, R.E. Langley
, et al.
·
Annals of Oncology
·
66
PDF
High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia
2005
·
L M El-Helw
, M J Seckl
, et al.
·
British Journal of Cancer
·
48
PDF
Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas
2009
·
J Zekri
, NLC Cheah
, et al.
·
The Journal of the Royal College of Physicians of Edinburgh
·
15
PDF
ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, oesophagogastric junction (OGJ) or lower oesophageal adenocarcinoma.
2012
·
Elizabeth C Smyth
, Ruth E Langley
, et al.
·
Journal of Clinical Oncology
·
14
Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Lesley Fairley
, Daniel P. Stark
, et al.
·
BMC Cancer
·
11
PDF
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin
2020
·
Robert Jones
, Simon Crabb
, et al.
·
British Journal of Urology
·
7
PDF
Enteropathy‐associated T‐cell lymphoma, lacking MHC class II, with immune‐privileged site recurrence, presenting as bilateral ocular vitreous humour involvement – a case report
2012
·
Hardeep Singh Mudhar
, Malee Fernando
, et al.
·
Histopathology
·
6
PDF
Poor outcome in adolescents with high-risk Hodgkin lymphoma
2008
·
R. Herbertson
, L. Evans
, et al.
·
International Journal of Oncology
·
6
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
2025
·
Gianmarco Leone
, Francesco Orlando
, et al.
·
JAMA Oncology
·
5
TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
2016
·
Robert J. Jones
, Simon J. Crabb
, et al.
·
Journal of Clinical Oncology
·
4
SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer
2018
·
S.J. Crabb
, S.J. Danson
, et al.
·
Annals of Oncology
Additional file 3: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 7: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 5: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 2: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 1: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 3: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 7: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Additional file 6: of Access to principal treatment centres and survival rates for children and young people with cancer in Yorkshire, UK
2017
·
Fairley, Lesley
, Stark, Daniel
, et al.
·
Figshare
Show more works
View as search
Works count:
30
Citation count:
1,980
H-index:
10
I10-index:
10
Year
Topic
Type
